SCHEMBL465130

SCHEMBL465130

C1=Cc2ccccc2OCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB2 P05107 1/20 0.48
ICAM1 P05362 1/20 0.48
ITGAL P20701 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43
CRHBP P24387 2/20 0.43
CRHR2 Q13324 2/20 0.43
HTT P42858 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
ABCG2 Q9UNQ0 1/20 0.37
ADORA3 P0DMS8 1/20 0.33
DRD1 P21728 1/20 0.33
SLC5A7 Q9GZV3 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR2C P28335 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7468068 0.88 ITGB2 (0.44) ITGB2ICAM1ITGALSMN1; SMN2LMNA
Fluoride SCHEMBL753890 0.80 ITGB2 (0.44) ITGB2ICAM1ITGALSMN1; SMN2LMNA
Fluoride SCHEMBL10947736 0.80 ITGB2 (0.44) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL29037332 0.79 ITGB2 (0.56) ITGB2ICAM1ITGALSMN1; SMN2LMNA
Fluoride SCHEMBL28217726 0.78 ITGB2 (0.42) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL2289180 0.77 CYP2B6 (0.43) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL9208 0.77 CYP2B6 (0.43) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL2281562 0.77 CYP2B6 (0.43) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL131072 0.77 ITGB2 (0.52) ITGB2ICAM1ITGALSMN1; SMN2LMNA
SCHEMBL29364609 0.77 CYP2B6 (0.43) ITGB2ICAM1ITGALSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2883865-A1 Compound capable of binding S1P receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2015-06-17 EP claimed
US-20140288034-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2014-09-25 US claimed
CN-102076737-A Novel polymers having low polydispersity MERCK PATENT GMBH 2011-05-25 CN claimed
US-20110095280-A1 NOVEL POLYMERS HAVING LOW POLYDISPERSITY MERCK PATENT GMBH (DE) 2011-04-28 US claimed
US-20110020324-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD (JP) 2011-01-27 US claimed
US-20070167425-A1 Compound capable of binding s1p receptor and pharmaceutical use thereof ONO PHARMACEUTICAL CO., LTD (JP) 2007-07-19 US claimed
EP-1661881-A2 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2006-05-31 EP claimed
US-20030018056-A1 Substituted guanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) 2003-01-23 US claimed
EP-1238971-A1 SUBSTITUTED GUANIDINE DERIVATIVES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-09-11 EP claimed
EP-0626954-A1 BENZOCYCLOHEPTENES, BENZOXEPINES AND BENZOTHIEPINES MERCK PATENT GmbH (DE) 1994-12-07 EP claimed
WO-1994013658-A2 BENZOCYCLOHEPTENES, BENZOXEPINES AND BENZOTHIEPINES MERCK PATENT GMBH (DE) 1994-06-23 WO claimed
US-20250154122-A1 PROCESS FOR THE PREPARATION OF COMPOUNDS COMPRISING A 2,5-DIHYDROBENZOXEPINE STRUCTURE BY PHOTOCHEMICAL REARRANGEMENT ECOLE POLYTECHNIQUE (FR) 2025-05-15 US disclosed
US-20250154122-A1 PROCESS FOR THE PREPARATION OF COMPOUNDS COMPRISING A 2,5-DIHYDROBENZOXEPINE STRUCTURE BY PHOTOCHEMICAL REARRANGEMENT ECOLE POLYTECHNIQUE (FR) 2025-05-15 US disclosed
CN-118984826-A Method for preparing compounds comprising 2, 5-dihydrobenzoxazepine structures by photochemical rearrangement 巴黎综合理工学院 2024-11-19 CN disclosed
CN-111148743-B Inhibition of ubiquitin-specific peptidase 30 福马治疗有限公司 2023-12-15 CN disclosed
WO-1994013658-A2 BENZOCYCLOHEPTENES, BENZOXEPINES AND BENZOTHIEPINES MERCK PATENT GMBH (DE) 1994-06-23 WO disclosed
US-5194442-A 2,3,4,5-tetrahydro-1-benzoxepins, the use thereof and pharmaceutical products based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1993-03-16 US disclosed
EP-0318235-A3 PAF ANTAGONIST, 1,4-DISUBSTITUTED PIPERAZINE COMPOUNDS AND PRODUCTION THEREOF Takeda Chemical Industries, Ltd. (JP) 1991-05-02 EP disclosed
EP-0360131-A1 2,3,4,5-Tetrahydro-1-benzoxepines, method for their preparation, their use and pharmaceutical compositions based on these compounds HOECHST AKTIENGESELLSCHAFT (DE) 1990-03-28 EP disclosed
EP-0318235-A2 PAF antagonist, 1,4-disubstituted piperazine compounds and production thereof Takeda Chemical Industries, Ltd. (JP) 1989-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250154122-A1 PROCESS FOR THE PREPARATION OF COMPOUNDS COMPRISING A 2,5-DIHYDROBENZOXEPINE STRUCTURE BY PHOTOCHEMICAL REARRANGEMENT DHPS, DDT, DHX15 ITGB2 4742/4885ICAM1 4787/4885ITGAL 4844/4885
US-20140288034-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF S1PR1, S1PR2, S1PR3 ITGB2 2718/4885ICAM1 713/4885ITGAL 2463/4885
US-20070167425-A1 Compound capable of binding s1p receptor and pharmaceutical use thereof S1PR1, S1PR3, S1PR2 ITGB2 3526/4885ICAM1 794/4885ITGAL 2774/4885
US-20110020324-A1 COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF S1PR1, S1PR3, S1PR2 ITGB2 3526/4885ICAM1 794/4885ITGAL 2774/4885
US-20030018056-A1 Substituted guanidine derivatives SLC28A1, SLC7A1, ABCB11 ITGB2 4410/4885ICAM1 4161/4885ITGAL 4726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.